We are monitoring the impact of COVID-19 on HIV Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 1980
Share on
Share on

Global HIV Therapeutics Market Analysis – By Drug Class, Application and Region - Size, Share, Trends, Growth Opportunities Assessment, Industry Forecast | 2019 – 2024

Pulished: February, 2020
ID: 1980
Pages: 175

Global HIV Therapeutics Market Size & Growth (2019 - 2024)

The size of the Global HIV Therapeutics Market was worth USD 13.57 billion in 2019 and estimated to be growing at a CAGR of 1.4%, to reach USD 14.55 billion by 2024 during the forecast period 2019 - 2024.

The human immunodeficiency virus (HIV) infection refers to a kind of retrovirus that causes (AIDS). HIV affects some immune cells and it weakens the immune system bringing about loss of capacity to fight against the organisms that cause diseases.

HIV spreads through the exchange of fluids with some infected individual, for example, blood exchange or imparting needles to somebody who is HIV infected. Additionally, HIV can spread from infected mother to child during pregnancy. Here are some of the symptoms of HIV disease are a slight fever, weakness, swollen glands, cerebral pains and muscle hurts. Integrase inhibitors section is expected to be the rapidly growing class of antiretroviral medications owing to the normal dispatch of extra integrase inhibitors by major players, for example, Gilead Sciences, In. and Merck and Co., Inc.

The availability of efficient therapies is one of the major factors which are boosting the growth of the global HIV therapeutics market. The growing prevalence of HIV/AIDS is leading to an increasing account of HIV therapies which is promoting the growth of the target market. The increasing number of initiatives to control the spread of the HIV epidemic is also propelling the growth of the market. Other factors that are boosting the growth of the global HIV therapeutics market are increasing awareness among people, approval of drugs, robust pipeline of medicines for HIV treatment, and rising healthcare expenditure.

 The social stigma associated with HIV infection is the major challenge for critical players in the market, which is obstructing the growth of the global HIV therapeutics market. Another major factor that is restraining the growth of the market is the high costs associated with antiretroviral therapies. Increasing resistance to drugs among patients is expected to be limiting the growth of the global HIV therapeutics market during the forecast period. 

Advancements in diagnostic testing for HIV and the emergence of various testing techniques such as rapid POC testing, ELSIA, viral load testing are creating lucrative opportunities for the key stakeholders in the market, and the HIV therapeutics market is likely to expand further over the forecast period. Increasing preference among people to use self-testing kits and HIV testing kits is providing a number of growth opportunities for the key players in the market. Increasing the adoption of mobile diagnostics tools for the detection of HIV in developing countries is offering growth opportunities for growth in the global HIV therapeutics market.

Key happenings in this market in the recent past:

PRODUCT LAUNCH

In July 2019, Merck Company launched a new drug for HIV patients called MK-8591, which has changed the dynamics of the company in the HIV therapeutics market. Also, the company has developed other medications for the treatment of HIV-1 such as PIFELTRO, and DELSTRIGO, which were released into the market after the completion of their approval by the U.S FDA in June 2018.

PRODUCT APPROVAL

In April 2019, ViiV Healthcare developed a drug called Dovato, which has been approved by the FDA in April 2019. The patients use the drug for the treatment of HIV-1 infection with a no-treatment history of ARV. 

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2018 – 2024

Base Year

2018

Forecast Period

2019 - 2024

Segments Covered

By Type, Application and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, APAC, Latin America, Middle East & Africa

Market Leaders Profiled

GlaxoSmithKline, Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, Merck, Hoffmann-La Roche and Gilead Sciences

 

This research report on the Global HIV Therapeutics Market segmented and sub-segmented into the following categories and analyzed market size and forecast for each segment until 2024.

HIV Therapeutics Market Analysis - By Type:

  • Nucleoside/Tide Reverse Transcriptase Inhibitors
  • Nucleoside/Tide Analogues
  • Non-Nucleoside Reverse Transcriptase Inhibitors
  • Protease Inhibitors
  • Integrase Inhibitors
  • CCR5 Inhibitors
  • Fusion Inhibitors

HIV Therapeutics Market Analysis - By Application:

  • HIV Type-1
  • HIV Type-2

Regional Analysis:

North America, trailed by Europe, has the highest market share for HIV therapeutics because of the affordability and availability of costly treatment for HIV infections and developments in medication treatments in this region. Asia is expected to show a high development rate in the HIV therapeutics market in the next couple of years because of an increasing number of HIV affected people and expanding research exercises for creating HIV medications and immunizations in the region.

List of key market players leading the Global HIV Therapeutics Market profiled in this report are:

  1. GlaxoSmithKline
  2. Bristol-Myers Squibb
  3. Pfizer
  4. Boehringer Ingelheim
  5. Merck
  6. Hoffmann-La Roche
  7. Gilead Sciences

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Drug Class                   

                                5.1.1 Introduction           

                                5.1.2 integrase inhibitor               

                                5.1.3 nucleoside/nucleotide reverse transcriptase inhibitor         

                                5.1.4  non-nucleoside turn around transcriptase inhibitor             

                                5.1.5 HIV-1 protease inhibitor    

                                5.1.6 pharmacokinetic enhancer              

                                5.1.7 passage inhibitor  

                                5.1.8  Y-o-Y Growth Analysis, Drug class                

                                5.1.9  Market Attractiveness Analysis, Drug class              

                                5.1.10  Market Share Analysis, Drug class              

                5.2 Application                 

                                5.2.1 Introduction           

                                5.2.2 HIV Type-1              

                                5.2.3 HIV Type-2              

                                5.2.4 Y-o-Y Growth Analysis, Application               

                                5.2.5 Market Attractiveness Analysis, Application             

                                5.2.6 Market Share Analysis, Application              

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 Drug Class

                                                6.1.3.3 HIV TYPE 1&2

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 Drug Class

                                                6.1.4.3 HIV TYPE 1&2

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 Drug Class

                                                6.1.5.3 HIV TYPE 1&2

                6.2 North America                          

                                6.1.1 Introduction           

                                6.1.2 United States         

                                6.1.3 Canada     

                6.3 Europe                         

                                6.2.1 Introduction           

                                6.2.2 U.K             

                                6.2.3 Spain         

                                6.2.4 Germany 

                                6.2.5 Italy            

                                6.2.6 France       

                6.4 Asia-Pacific                 

                                6.3.1 Introduction           

                                6.3.2 China         

                                6.3.3 India          

                                6.3.4 Japan         

                                6.3.5 Australia   

                                6.3.6 South Korea           

                6.5 Latin America                             

                                6.4.1 Introduction           

                                6.4.2 Brazil          

                                6.4.3 Argentina

                                6.4.4 Mexico     

                                6.4.5 Rest of Latin America          

                6.6 Middle East & Africa                               

                                6.5.1 Introduction           

                                6.5.2 Middle-East            

                                6.5.3 Africa         

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8.Market Leaders' Analysis                                         

                8.1 Athersys                      

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 StemCells                    

                8.3 Cryo Cell International                           

                8.4 Geron Corporation                  

                8.5 Mesoblast                   

                8.6 Aastrom Biosciences                              

                8.7 Celgene Corporation                              

                8.8 Invitrogen                   

                8.9 Cytori Therapeutics                 

                8.10 Retractable Technologies                   

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10.Market Outlook and Investment Opportunities                                          

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Global, regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Global HIV Therapeutics Market By Region, From 2019-2024 ( USD Million )
  2. Global HIV Therapeutics Market By Type, From 2019-2024 ( USD Million )
  3. Global Nucleoside/tide reverse transcriptase inhibitors or nucleoside/tide analogues Market By Region, From 2019-2024 ( USD Million )
  4. Global Non-nucleoside reverse transcriptase inhibitors Market By Region, From 2019-2024 ( USD Million )
  5. Global Protease inhibitors Market By Region, From 2019-2024 ( USD Million )
  6. Global Integrate [strand transfer] inhibitors Market By Region, From 2019-2024 ( USD Million )
  7. Global Fusion inhibitors Market By Region, From 2019-2024 ( USD Million )
  8. Global HIV Therapeutics Market By Application, From 2019-2024 ( USD Million )
  9. Global HIV Type 1 Market By Region, From 2019-2024 ( USD Million )
  10. Global HIV Type 2 Market By Region, From 2019-2024 ( USD Million )
  11. North America HIV Therapeutics Market By Type, From 2019-2024 ( USD Million )
  12. North America Nucleoside/tide reverse transcriptase inhibitors or nucleoside/tide analogues Market By Region, From 2019-2024 ( USD Million )
  13. North America Non-nucleoside reverse transcriptase inhibitors Market By Region, From 2019-2024 ( USD Million )
  14. North America Protease inhibitors Market By Region, From 2019-2024 ( USD Million )
  15. North America Integrate [strand transfer] inhibitors Market By Region, From 2019-2024 ( USD Million )
  16. North America Fusion inhibitors Market By Region, From 2019-2024 ( USD Million )
  17. North America HIV Therapeutics Market By Application, From 2019-2024 ( USD Million )
  18. North America HIV Type 1 Market By Region, From 2019-2024 ( USD Million )
  19. North America HIV Type 2 Market By Region, From 2019-2024 ( USD Million )
  20. United States HIV Therapeutics Market By Type, From 2019-2024 ( USD Million )
  21. United States HIV Therapeutics Market By Application, From 2019-2024 ( USD Million )
  22. Canada HIV Therapeutics Market By Type, From 2019-2024 ( USD Million )
  23. Canada HIV Therapeutics Market By Application, From 2019-2024 ( USD Million )
  24. Europe HIV Therapeutics Market By Type, From 2019-2024 ( USD Million )
  25. Europe Nucleoside/tide reverse transcriptase inhibitors or nucleoside/tide analogues Market By Region, From 2019-2024 ( USD Million )
  26. Europe Non-nucleoside reverse transcriptase inhibitors Market By Region, From 2019-2024 ( USD Million )
  27. Europe Protease inhibitors Market By Region, From 2019-2024 ( USD Million )
  28. Europe Integrate [strand transfer] inhibitors Market By Region, From 2019-2024 ( USD Million )
  29. Europe Fusion inhibitors Market By Region, From 2019-2024 ( USD Million )
  30. Europe HIV Therapeutics Market By Application, From 2019-2024 ( USD Million )
  31. Europe HIV Type 1 Market By Region, From 2019-2024 ( USD Million )
  32. Europe HIV Type 2 Market By Region, From 2019-2024 ( USD Million )
  33. U.K. HIV Therapeutics Market By Type, From 2019-2024 ( USD Million )
  34. U.K. HIV Therapeutics Market By Application, From 2019-2024 ( USD Million )
  35. Germany HIV Therapeutics Market By Type, From 2019-2024 ( USD Million )
  36. Germany HIV Therapeutics Market By Application, From 2019-2024 ( USD Million )
  37. France HIV Therapeutics Market By Type, From 2019-2024 ( USD Million )
  38. France HIV Therapeutics Market By Application, From 2019-2024 ( USD Million )
  39. Italy HIV Therapeutics Market By Type, From 2019-2024 ( USD Million )
  40. Italy HIV Therapeutics Market By Application, From 2019-2024 ( USD Million )
  41. Spain HIV Therapeutics Market By Type, From 2019-2024 ( USD Million )
  42. Spain HIV Therapeutics Market By Application, From 2019-2024 ( USD Million )
  43. Asia-Pacific HIV Therapeutics Market By Type, From 2019-2024 ( USD Million )
  44. Asia-Pacific Nucleoside/tide reverse transcriptase inhibitors or nucleoside/tide analogues Market By Region, From 2019-2024 ( USD Million )
  45. Asia-Pacific Non-nucleoside reverse transcriptase inhibitors Market By Region, From 2019-2024 ( USD Million )
  46. Asia-Pacific Protease inhibitors Market By Region, From 2019-2024 ( USD Million )
  47. Asia-Pacific Integrate [strand transfer] inhibitors Market By Region, From 2019-2024 ( USD Million )
  48. Asia-Pacific Fusion inhibitors Market By Region, From 2019-2024 ( USD Million )
  49. Asia-Pacific HIV Therapeutics Market By Application, From 2019-2024 ( USD Million )
  50. Asia-Pacific HIV Type 1 Market By Region, From 2019-2024 ( USD Million )
  51. Asia-Pacific HIV Type 2 Market By Region, From 2019-2024 ( USD Million )
  52. Japan HIV Therapeutics Market By Type, From 2019-2024 ( USD Million )
  53. Japan HIV Therapeutics Market By Application, From 2019-2024 ( USD Million )
  54. China HIV Therapeutics Market By Type, From 2019-2024 ( USD Million )
  55. China HIV Therapeutics Market By Application, From 2019-2024 ( USD Million )
  56. India HIV Therapeutics Market By Type, From 2019-2024 ( USD Million )
  57. India HIV Therapeutics Market By Application, From 2019-2024 ( USD Million )
  58. Australia HIV Therapeutics Market By Type, From 2019-2024 ( USD Million )
  59. Australia HIV Therapeutics Market By Application, From 2019-2024 ( USD Million )
  60. South Korea HIV Therapeutics Market By Type, From 2019-2024 ( USD Million )
  61. South Korea HIV Therapeutics Market By Application, From 2019-2024 ( USD Million )
  62. Latin America HIV Therapeutics Market By Type, From 2019-2024 ( USD Million )
  63. Latin America Nucleoside/tide reverse transcriptase inhibitors or nucleoside/tide analogues Market By Region, From 2019-2024 ( USD Million )
  64. Latin America Non-nucleoside reverse transcriptase inhibitors Market By Region, From 2019-2024 ( USD Million )
  65. Latin America Protease inhibitors Market By Region, From 2019-2024 ( USD Million )
  66. Latin America Integrate [strand transfer] inhibitors Market By Region, From 2019-2024 ( USD Million )
  67. Latin America Fusion inhibitors Market By Region, From 2019-2024 ( USD Million )
  68. Latin America HIV Therapeutics Market By Application, From 2019-2024 ( USD Million )
  69. Latin America HIV Type 1 Market By Region, From 2019-2024 ( USD Million )
  70. Latin America HIV Type 2 Market By Region, From 2019-2024 ( USD Million )
  71. Brazil HIV Therapeutics Market By Type, From 2019-2024 ( USD Million )
  72. Brazil HIV Therapeutics Market By Application, From 2019-2024 ( USD Million )
  73. Argentina HIV Therapeutics Market By Type, From 2019-2024 ( USD Million )
  74. Argentina HIV Therapeutics Market By Application, From 2019-2024 ( USD Million )
  75. Mexico HIV Therapeutics Market By Type, From 2019-2024 ( USD Million )
  76. Mexico HIV Therapeutics Market By Application, From 2019-2024 ( USD Million )
  77. Rest of Latin America HIV Therapeutics Market By Type, From 2019-2024 ( USD Million )
  78. Rest of Latin America HIV Therapeutics Market By Application, From 2019-2024 ( USD Million )
  79. Middle East & Africa HIV Therapeutics Market By Type, From 2019-2024 ( USD Million )
  80. Middle East & Africa Nucleoside/tide reverse transcriptase inhibitors or nucleoside/tide analogues Market By Region, From 2019-2024 ( USD Million )
  81. Middle East & Africa Non-nucleoside reverse transcriptase inhibitors Market By Region, From 2019-2024 ( USD Million )
  82. Middle East & Africa Protease inhibitors Market By Region, From 2019-2024 ( USD Million )
  83. Middle East & Africa Integrate [strand transfer] inhibitors Market By Region, From 2019-2024 ( USD Million )
  84. Middle East & Africa Fusion inhibitors Market By Region, From 2019-2024 ( USD Million )
  85. Middle East & Africa HIV Therapeutics Market By Application, From 2019-2024 ( USD Million )
  86. Middle East & Africa HIV Type 1 Market By Region, From 2019-2024 ( USD Million )
  87. Middle East & Africa HIV Type 2 Market By Region, From 2019-2024 ( USD Million )
  88. Middle East HIV Therapeutics Market By Type, From 2019-2024 ( USD Million )
  89. Middle East HIV Therapeutics Market By Application, From 2019-2024 ( USD Million )
  90. Africa HIV Therapeutics Market By Type, From 2019-2024 ( USD Million )
  91. Africa HIV Therapeutics Market By Application, From 2019-2024 ( USD Million )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample